1. CF33 Proposed Phase 1/2 Clinical Development Plan

2. Open Label Phase 1b in Gastric Cancer, in Combination with Chemotherapy (HER-Vaxx), Recruiting in Asia & Eastern Europe.

More Information Here


3. Open Label Phase 2, HER2 Positive (over expression of HER2 receptor) in Various Indications Recruiting at Ohio State University.

More Information Here